论文部分内容阅读
目的探讨沐舒坦雾化吸入治疗新生儿肺炎的疗效并进行分析。方法选取2012年1月~2013年1月间于本院收治的80例患肺炎新生儿作为研究对象,随机分为治疗组和对照组。对照组给予常规治疗,治疗组在对照组的基础上,加用沐舒坦雾化吸入治疗。观察比较两组的治疗效果及副作用出现情况。结果经实施不同治疗方案后,治疗组的治疗效果和平均治疗时间均显著优于对照组,差异有统计学意义(P值均<0.05),两组的副作用发生率差异无统计学意义。结论沐舒坦雾化吸入用于治疗新生儿肺炎疗效较好,可迅速缓解呼吸道症状,缩短治疗时间和住院时间,值得临床推广。
Objective To investigate the efficacy and safety of mucosolvan inhalation in the treatment of neonatal pneumonia. Methods Eighty newborns with pneumonia admitted to our hospital from January 2012 to January 2013 were randomly divided into treatment group and control group. The control group were given routine treatment, the treatment group in the control group based on the addition of mucosolvan inhalation therapy. Observation and comparison of the two groups of treatment and side effects occurred. Results After different treatment regimens, the treatment effect and average treatment time of the treatment group were significantly better than the control group, the difference was statistically significant (P all <0.05). There was no significant difference in the incidence of side effects between the two groups. Conclusion Mucosolvan inhalation for the treatment of neonatal pneumonia better efficacy, can quickly relieve respiratory symptoms, shorten the treatment time and hospital stay, worthy of clinical promotion.